Lifescience
Cholera Treatment Market Size Forecast to Reach $167.89 Million by 2025
Cholera Treatment Market size is forecast to reach $167.89 Million by 2025, growing at a CAGR of 8.53% during the forecast period 2020-2025. Cholera is an infectious disease that causes severe watery diarrhea, which can lead to dehydration and even death if untreated. It is caused by eating food or drinking water contaminated with a bacterium called Vibrio cholerae. Cholera requires immediate treatment as the disease can cause death within hours. Rehydration therapy, intravenous fluids, antibiotic treatment, and zinc supplements are primary treatment options for cholera. Rise in number of affected and mortality cases owing to cholera epidemic, unclean environments for pollution and lack of sanitary systems, massive awareness campaigns by government & NGOs and increase in financial investment and support for development of novel medications by key investment firms and market players are major factors that are driving the market growth in recent years. In addition, major developments by key market players like Sanofi and Novartis is also driving the growth of the market.
Key Takeaways
- Asia-Pacific dominated the Cholera Treatment Market in the year 2019 owing to rising prevalence of cholera disease among a large section of the population and growing awareness about treatment of the diseases, The Cholera Treatment Market scope for different regions will be provided in the final report.
- Rise in number of cases of affected and deaths by cholera, increasing awareness about cholera treatment, launch of oral vaccines by key market players and favorable government policies for vaccine launches and novel drug R&D studies have helped in significant growth of Cholera Treatment Market.
- Detailed analysis on the Strength, Weakness and Opportunities of the prominent players operating in the market will be provided in the Cholera Treatment Market report.
- Lack of healthcare awareness in some less developed countries is anticipated to hamper the market growth of the Cholera Treatment Industry.
- Rise in number of cases of affected people and death from cholera
- Government initiatives to vaccine launches and immunization
- Lack of healthcare awareness in some less developed countries
- In January 2020, Emergent BioSolutions Inc. announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for the approval of the company’s single-dose oral cholera vaccine, Vaxchora (Cholera Vaccine, Live, Oral).
- In February 2018, WHO approved Cholera vaccine from Shantha Biotechnics (part of Sanofi) for use at temperatures as high as 40°C for up to 14 days, immediately prior to administration.
- In September 2018, Novartis partnered with its division, Sandoz and DSV, a world-leading supplier of transport and logistics services to donate one million rands worth of medicines towards cholera outbreak in Zimbabwe.






